Withdrawn ID: | w235 |
---|---|
Canonical SMILES: | |
Standard InChI: | |
Standard InChIKey: | |
ATC class(es): | N06AX03 |
Molecular Formula: | C18H20N2 |
Molweight: | 264.365 |
Withdrawn due to drug safety reasons: | Yes |
---|---|
First approved: | 1976 |
First withdrawn: | 1988 |
Last withdrawn: | 1988 |
Reference: | https://www.ncbi.nlm.nih.gov/pubmed/10942986 |
Total reported cases (submitted by medical professionals) with Mianserin as primary suspect: | 6 |
---|
Hospitalization (initial or prolonged): | 4 |
---|---|
Death: | 1 |
Side-effect | Case number |
---|---|
Somnolence | 2 |
DRUG INTERACTION | 2 |
Hepatocellular injury | 1 |
ACUTE RESPIRATORY FAILURE | 1 |
Cholestasis | 1 |
Cognitive disorder | 1 |
CONDITION AGGRAVATED | 1 |
Drug abuse | 1 |
Drug reaction with eosinophilia and systemic symptoms | 1 |
Eosinophilia | 1 |
Face oedema | 1 |
General physical health deterioration | 1 |
Hepatitis | 1 |
TOXICITY TO VARIOUS AGENTS | 1 |
Hyperthermia | 1 |
HYPOTHYROIDISM | 1 |
Lymphocytosis | 1 |
Prescription form tampering | 1 |
Rash morbilliform | 1 |
SEROTONIN SYNDROME | 1 |
Subdural haematoma | 1 |
SUICIDE ATTEMPT | 1 |
THERAPEUTIC RESPONSE UNEXPECTED | 1 |
Target UniProtKB ID | Activity in nm | Target Name | Target gene |
---|---|---|---|
P02545 | 158.5 | Prelamin-A/C | LMNA_HUMAN |
P08913 | 4.8 | Alpha-2A adrenergic receptor | ADA2A_HUMAN |
P14416 | 2197 | D(2) dopamine receptor | DRD2_HUMAN |
P18825 | 3.8 | Alpha-2C adrenergic receptor | ADA2C_HUMAN |
P28223 | 1.2 | 5-hydroxytryptamine receptor 2A | 5HT2A_HUMAN |
P28335 | 1.7 | 5-hydroxytryptamine receptor 2C | 5HT2C_HUMAN |
P34969 | 56 | 5-hydroxytryptamine receptor 7 | 5HT7R_HUMAN |
P35367 | 1.7 | Histamine H1 receptor | HRH1_HUMAN |
P35462 | 2841 | D(3) dopamine receptor | DRD3_HUMAN |
P50406 | 55 | 5-hydroxytryptamine receptor 6 | 5HT6R_HUMAN |
Toxicity class: | 4 |
---|---|
Toxicity type: | hematological |
LD50: | 370 mg/kg |
ChEBML: | CHEMBL6437 |
---|---|
DrugBank: | DB06148 |